Last reviewed · How we verify
TR-701 free acid phosphate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
TR-701 free acid phosphate (TR-701 free acid phosphate) — Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TR-701 free acid phosphate TARGET | TR-701 free acid phosphate | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TR-701 free acid phosphate CI watch — RSS
- TR-701 free acid phosphate CI watch — Atom
- TR-701 free acid phosphate CI watch — JSON
- TR-701 free acid phosphate alone — RSS
Cite this brief
Drug Landscape (2026). TR-701 free acid phosphate — Competitive Intelligence Brief. https://druglandscape.com/ci/tr-701-free-acid-phosphate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab